Saturday, July 11, 2026

Patent directory · USPTO A61K / A61P

Patents matching “regimen”

70 pharma patents match "regimen" in our USPTO index (A61K/A61P) — applicant, grant date, expiration, and drug links.

Matches 70
Index total 30,257
Page 1 / 3

Quick answer

This filtered view shows 70 pharmaceutical patents matching "regimen" in our USPTO PatentsView index (CPC A61K/A61P). Search matches patent number, title, applicant, and CPC classification codes.

Patent results

70 results for “regimen” · 30,257 patents in full index Clear search

  1. US 20260060930

    New crystalline Forms, new pharmaceutical Composition and Dose Regimen of a Dipeptidyl peptidase I inhibitor for the Treatment of Patients with Bronchiectasis or other DPP-I mediated Diseases

    BOEHRINGER INGELHEIM INT [DE] · Granted Mar 5, 2026 · Expires Feb 28, 2046

    granted
  2. US 12390463

    Dosage forms and regimens for amino acid compounds

    Pliant Therapeutics, Inc. · Granted Aug 19, 2025 · Expires Aug 14, 2045

    granted
  3. US 12370181

    Regimens of estrogen receptor antagonists

    Olema Pharmaceuticals, Inc. · Granted Jul 29, 2025 · Expires Jul 24, 2045

    granted
  4. US 12370163

    Levodopa dosing regimen

    AMNEAL PHARMACEUTICALS LLC · Granted Jul 29, 2025 · Expires Jul 24, 2045

    granted
  5. US 12364683

    Non-sedating dexmedetomidine treatment regimens

    BioXcel Therapeutics, Inc. · Granted Jul 22, 2025 · Expires Jul 17, 2045

    granted
  6. US 12343381

    Dosage regimen for pegylated interferon

    PHARMAESSENTIA CORPORATION · Granted Jul 1, 2025 · Expires Jun 26, 2045

    granted
  7. US 12336980

    Dosing regimen for a selective S1P1 receptor agonist

    VANDA PHARMACEUTICALS INC. · Granted Jun 24, 2025 · Expires Jun 19, 2045

    granted
  8. US 12303482

    Levodopa dosing regimen

    AMNEAL PHARMACEUTICALS LLC · Granted May 20, 2025 · Expires May 15, 2045

    granted
  9. US 12303481

    Levodopa dosing regimen

    AMNEAL PHARMACEUTICALS LLC · Granted May 20, 2025 · Expires May 15, 2045

    granted
  10. US 12295931

    Levodopa dosing regimen

    AMNEAL PHARMACEUTICALS LLC · Granted May 13, 2025 · Expires May 8, 2045

    granted
  11. US 12290566

    Dosing regimens and related compositions and methods

    Apellis Pharmaceuticals, Inc. · Granted May 6, 2025 · Expires May 1, 2045

    granted
  12. US 12263149

    Levodopa dosing regimen

    AMNEAL PHARMACEUTICALS LLC · Granted Apr 1, 2025 · Expires Mar 27, 2045

    granted
  13. US 12263148

    Levodopa dosing regimen

    AMNEAL PHARMACEUTICALS LLC · Granted Apr 1, 2025 · Expires Mar 27, 2045

    granted
  14. US 12213989

    Use of maribavir in treatment regimens

    Takeda Pharmaceutical Company Limited · Granted Feb 4, 2025 · Expires Jan 30, 2045

    granted
  15. US 12201596

    Levodopa dosing regimen

    AMNEAL PHARMACEUTICALS LLC · Granted Jan 21, 2025 · Expires Jan 16, 2045

    granted
  16. US 12194079

    Therapeutic regimen for the treatment of Fabry using stabilized alpha-galactosidase

    Protalix Ltd. · Granted Jan 14, 2025 · Expires Jan 9, 2045

    granted
  17. US 12194150

    Levodopa dosing regimen

    AMNEAL PHARMACEUTICALS LLC · Granted Jan 14, 2025 · Expires Jan 9, 2045

    granted
  18. US 12138247

    Non-sedating dexmedetomidine treatment regimens

    BioXcel Therapeutics, Inc. · Granted Nov 12, 2024 · Expires Nov 7, 2044

    granted
  19. US 12109196

    Non-sedating dexmedetomidine treatment regimens

    BioXcel Therapeutics, Inc. · Granted Oct 8, 2024 · Expires Oct 3, 2044

    granted
  20. US 12109185

    Levodopa dosing regimen

    AMNEAL PHARMACEUTICALS LLC · Granted Oct 8, 2024 · Expires Oct 3, 2044

    granted
  21. US 12090140

    Non-sedating dexmedetomidine treatment regimens

    BioXcel Therapeutics, Inc. · Granted Sep 17, 2024 · Expires Sep 12, 2044

    granted
  22. US 12029788

    Methods for increasing lean body mass with an exercise regimen and a GDF8 inhibitor that is an anti-GDF8 antibody

    REGENERON PHARMACEUTICALS, INC. · Granted Jul 9, 2024 · Expires Jul 4, 2044

    granted
  23. US 11998528

    Non-sedating dexmedetomidine treatment regimens

    BioXcel Therapeutics, Inc. · Granted Jun 4, 2024 · Expires May 30, 2044

    granted
  24. US 11998529

    Non-sedating dexmedetomidine treatment regimens

    BioXcel Therapeutics, Inc. · Granted Jun 4, 2024 · Expires May 30, 2044

    granted